GM Life MP2 Tablet ER is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Pioglitazone 15mg, formulated for extended release to provide sustained glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake in muscle tissues. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved insulin action in adipose tissue, muscle, and the liver. The extended-release formulation ensures gradual drug release, minimizing gastrointestinal side effects commonly associated with Metformin and promoting better patient adherence. GM Life MP2 Tablet ER is indicated for patients inadequately controlled on monotherapy or dual therapy with these agents and is intended as part of a comprehensive diabetes management plan including diet and exercise. Caution is advised in patients with hepatic or renal impairment, heart failure, or a history of lactic acidosis. Regular monitoring of blood glucose, liver function, and cardiac status is recommended during therapy to optimize safety and efficacy.